A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...

This CAR helps the T cells recognize and destroy cells expressing BCMA, which is primarily found in malignant multiple myeloma B-lineage cells, late-stage B cells, and plasma cells. The CARVYKTI ...

While teclistamab looks on course to be the first BCMA-targeting bispecific antibody to reach the market, Pfizer is hot on J&J's heels with its BCMAxCD3 drug elranatamab and reported phase 2 data ...

Panelists discuss how recent clinical trials have demonstrated promising outcomes in late-line relapsed/refractory multiple myeloma (RRMM) with bispecific antibodies targeting B-cell maturation ...

The double-headed antibody binds to CD3 on T cells and redirects them to BCMA-expressing myeloma cells, with the aim of stimulating an immune attack on the tumour, which remains incurable despite ...

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

In spite of recent advances in the management of multiple myeloma, cure has been elusive ... T-cell therapies targeting B-cell maturation antigen (BCMA) had a huge impact on prolonging survival ...

BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents. A recent study suggests that a patient’s immune ...